Stifel Nicolaus Boosts Waters (NYSE:WAT) Price Target to $220.00

Waters (NYSE:WAT) had its price objective lifted by Stifel Nicolaus from $180.00 to $220.00 in a report issued on Wednesday, BenzingaRatingsTable reports. The brokerage currently has a hold rating on the medical instruments supplier’s stock.

WAT has been the subject of several other reports. JPMorgan Chase & Co. upgraded shares of Waters from an underweight rating to a neutral rating in a report on Tuesday, July 28th. Zacks Investment Research upgraded shares of Waters from a sell rating to a hold rating and set a $210.00 price target for the company in a research note on Monday, June 1st. Wells Fargo & Co upgraded shares of Waters from an underweight rating to an equal weight rating and increased their price target for the stock from $175.00 to $225.00 in a research note on Thursday, July 16th. Citigroup increased their price target on shares of Waters from $150.00 to $180.00 and gave the stock a sell rating in a research note on Wednesday. Finally, UBS Group decreased their price target on shares of Waters from $223.00 to $212.00 and set a neutral rating for the company in a research note on Tuesday, April 28th. Four research analysts have rated the stock with a sell rating and eight have given a hold rating to the company. Waters presently has a consensus rating of Hold and an average target price of $196.22.

Shares of WAT opened at $213.15 on Wednesday. The stock has a market capitalization of $13.17 billion, a P/E ratio of 26.54, a PEG ratio of 6.89 and a beta of 0.94. The firm has a fifty day simple moving average of $197.00 and a two-hundred day simple moving average of $199.83. Waters has a twelve month low of $154.39 and a twelve month high of $245.68.

Waters (NYSE:WAT) last announced its quarterly earnings results on Tuesday, July 28th. The medical instruments supplier reported $2.10 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $1.47 by $0.63. The business had revenue of $519.98 million during the quarter, compared to analysts’ expectations of $519.41 million. Waters had a net margin of 22.61% and a negative return on equity of 349.31%. On average, analysts predict that Waters will post 8.2 earnings per share for the current fiscal year.

A number of large investors have recently added to or reduced their stakes in the business. Ledyard National Bank increased its stake in Waters by 3.6% during the 2nd quarter. Ledyard National Bank now owns 1,437 shares of the medical instruments supplier’s stock valued at $259,000 after purchasing an additional 50 shares in the last quarter. Brinker Capital Inc. boosted its holdings in shares of Waters by 4.1% during the 1st quarter. Brinker Capital Inc. now owns 1,671 shares of the medical instruments supplier’s stock valued at $304,000 after acquiring an additional 66 shares during the last quarter. Oppenheimer Asset Management Inc. boosted its holdings in shares of Waters by 9.8% during the 1st quarter. Oppenheimer Asset Management Inc. now owns 785 shares of the medical instruments supplier’s stock valued at $143,000 after acquiring an additional 70 shares during the last quarter. Wesleyan Assurance Society boosted its holdings in shares of Waters by 0.8% during the 1st quarter. Wesleyan Assurance Society now owns 10,180 shares of the medical instruments supplier’s stock valued at $1,853,000 after acquiring an additional 80 shares during the last quarter. Finally, Armstrong Henry H Associates Inc. boosted its holdings in shares of Waters by 1.0% during the 1st quarter. Armstrong Henry H Associates Inc. now owns 8,169 shares of the medical instruments supplier’s stock valued at $1,487,000 after acquiring an additional 80 shares during the last quarter. Institutional investors and hedge funds own 95.09% of the company’s stock.

About Waters

Waters Corporation, a specialty measurement company, provides analytical workflow solutions in Asia, the Americas, and Europe. It operates through two segments, Waters and TA. The company designs, manufactures, sells, and services high and ultra-performance liquid chromatography, as well as mass spectrometry (MS) technology systems and support products, including chromatography columns, other consumable products, and post-warranty service plans.

Further Reading: Cost of Equity For A Business, Investors

Analyst Recommendations for Waters (NYSE:WAT)

Receive News & Ratings for Waters Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Waters and related companies with MarketBeat.com's FREE daily email newsletter.